Seattle Genetics Announces Updates to ADCETRIS Prescribing Information

Seattle Genetics, Inc.

today announced updates to the U.S. Prescribing Information for ADCETRIS™ (brentuximab vedotin). The revised PI will include the following updated information: A boxed warning related to the risk that JC virus infection resulting in progressive multifocal leukoencephalopathy and death can occur in patients receiving ADCETRIS. A discussion in the PML warning and precaution provision regarding other possible contributing factors to PML such as other prior therapies and underlying disease, symptoms to be aware of and suggested methodologies for diagnosis of PML. A contraindication warning of the concomitant use of ADCETRIS and bleomycin due to pulmonary toxicity.